A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Durvalumab (Primary) ; Ociperlimab (Primary) ; Tislelizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms AdvanTIG-301
- Sponsors BeiGene
- 17 Jan 2024 Status changed from recruiting to discontinued.
- 04 Oct 2023 This trial has been discontinued in Spain (Global end date: 11 July 2023).
- 07 Aug 2023 This trial has been discontinued in Germany (End Date: 11 Jul 2023), according to European Clinical Trials Database record.